Production (Stage)
EyePoint Pharmaceuticals, Inc.
EYPT
$9.03
$0.171.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.04% | -5.97% | 7.50% | 34.98% | 25.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.04% | -5.97% | 7.50% | 34.98% | 25.70% |
| Cost of Revenue | 90.70% | 95.62% | 57.58% | 54.94% | 39.74% |
| Gross Profit | -203.91% | -304.30% | -136.94% | -83.53% | -66.53% |
| SG&A Expenses | 7.05% | 4.97% | -2.40% | -13.75% | -13.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.87% | 56.19% | 30.91% | 21.07% | 12.18% |
| Operating Income | -85.84% | -94.30% | -43.08% | -15.01% | -5.63% |
| Income Before Tax | -86.08% | -84.95% | -3.33% | 18.14% | 23.05% |
| Income Tax Expenses | 8.43% | 8.43% | -- | -- | -- |
| Earnings from Continuing Operations | -86.00% | -84.86% | -3.42% | 18.06% | 22.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.00% | -84.86% | -3.42% | 18.06% | 22.97% |
| EBIT | -85.84% | -94.30% | -43.08% | -15.01% | -5.63% |
| EBITDA | -85.25% | -93.44% | -42.83% | -15.70% | -7.25% |
| EPS Basic | -31.81% | -25.87% | 24.76% | 36.56% | 33.36% |
| Normalized Basic EPS | -34.52% | -28.44% | 3.49% | 19.95% | 18.21% |
| EPS Diluted | -31.81% | -25.87% | 24.76% | 36.56% | 33.36% |
| Normalized Diluted EPS | -34.52% | -28.44% | 3.49% | 19.95% | 18.21% |
| Average Basic Shares Outstanding | 41.51% | 44.71% | 34.48% | 24.62% | 14.38% |
| Average Diluted Shares Outstanding | 41.51% | 44.71% | 34.48% | 24.62% | 14.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |